Literature DB >> 17132385

Withdrawal from long-term benzodiazepine use: randomised trial in family practice.

Catalina Vicens1, Francisca Fiol, Joan Llobera, Francisco Campoamor, Catalina Mateu, Santiago Alegret, Isabel Socías.   

Abstract

BACKGROUND: The long-term use of benzodiazepines is highly prevalent in developed societies and is not devoid of risks. Withdrawing patients from these drugs is often difficult. Tapering off benzodiazepines has been shown to be a good strategy for discontinuing their long-term use. AIM: To establish the efficacy of an intervention programme for reducing the chronic use of benzodiazepines. DESIGN OF STUDY: Randomised, two-arm, parallel, non-blinded controlled trial.
SETTING: Three urban healthcare centres covering a population of 50,000 inhabitants (Mallorca, Spain).
METHOD: Adult patients (n = 139) taking benzodiazepines daily for more than a year and visited by their family physician were randomised into an intervention group (n = 73) that received standardised advice and a tapering off schedule with biweekly follow-up visits, or into a control group (n = 66), that was managed following routine clinical practice. Both were followed for a year.
RESULTS: Patients achieved withdrawal or reduced their dose by at least 50% after 6 and 12 months. Abstinence and withdrawal symptoms were also measured. Both groups were homogeneous for personal, clinical and psychological characteristics and for benzodiazepine use. Only two patients from each group were lost to follow-up. After 12 months, 33 (45.2%) patients in the intervention group and six (9.1%) in the control group had discontinued benzodiazepine use; relative risk = 4.97 (95% confidence interval [CI] = 2.2 to 11.1), absolute risk reduction = 0.36 (95% CI = 0.22 to 0.50). For every three interventions, one patient achieved withdrawal. Sixteen (21.9%) subjects from the intervention group and 11 (16.7%) controls reduced their initial dose by more than 50%.
CONCLUSION: Standardised advice given by the family physician, together with a tapering off schedule, is effective for withdrawing patients from long-term benzodiazepine use and is feasible in primary care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17132385      PMCID: PMC1934057     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  14 in total

Review 1.  Pharmacologic strategies for discontinuing benzodiazepine treatment.

Authors:  K Rickels; N DeMartinis; M Rynn; L Mandos
Journal:  J Clin Psychopharmacol       Date:  1999-12       Impact factor: 3.153

Review 2.  Psychological strategies for discontinuing benzodiazepine treatment.

Authors:  D A Spiegel
Journal:  J Clin Psychopharmacol       Date:  1999-12       Impact factor: 3.153

3.  Chronic benzodiazepine use in general practice patients with depression: an evaluation of controlled treatment and taper-off: report on behalf of the Dutch Chronic Benzodiazepine Working Group.

Authors:  F G Zitman; J E Couvée
Journal:  Br J Psychiatry       Date:  2001-04       Impact factor: 9.319

4.  [Sleep disorders and the consumption of hypnotics on the island of Mallorca].

Authors:  F Cañellas Dols; J Ochogavia Cánaves; J Llobera Cánaves; A Palmer Pol; J Castell Colom; C Iglesias Tamargo
Journal:  Rev Clin Esp       Date:  1998-11       Impact factor: 1.556

Review 5.  Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management.

Authors:  E Schweizer; K Rickels
Journal:  Acta Psychiatr Scand Suppl       Date:  1998

6.  Evaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practice.

Authors:  M A Cormack; K G Sweeney; H Hughes-Jones; G A Foot
Journal:  Br J Gen Pract       Date:  1994-01       Impact factor: 5.386

7.  Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial.

Authors:  Lucie Baillargeon; Philippe Landreville; René Verreault; Jean-Pierre Beauchemin; Jean-Pierre Grégoire; Charles M Morin
Journal:  CMAJ       Date:  2003-11-11       Impact factor: 8.262

8.  Consensus on drug treatment, definition and diagnosis for insomnia.

Authors:  E Estivill; A Bové; D García-Borreguero; J Gibert; J Paniagua; G Pin; F J Puertas; R Cilveti
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

9.  Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life.

Authors:  R M Herings; B H Stricker; A de Boer; A Bakker; F Sturmans
Journal:  Arch Intern Med       Date:  1995-09-11

10.  Controlled evaluation of brief intervention by general practitioners to reduce chronic use of benzodiazepines.

Authors:  K Bashir; M King; M Ashworth
Journal:  Br J Gen Pract       Date:  1994-09       Impact factor: 5.386

View more
  16 in total

1.  How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials.

Authors:  Antonia F H Smelt; Gerda M van der Weele; Jeanet W Blom; Jacobijn Gussekloo; Willem J J Assendelft
Journal:  Br J Gen Pract       Date:  2010-07       Impact factor: 5.386

2.  Barriers to nonpharmacologic treatments for stress, anxiety, and insomnia: family physicians' attitudes toward benzodiazepine prescribing.

Authors:  Sibyl Anthierens; Inge Pasteels; Hilde Habraken; Pascale Steinberg; Tom Declercq; Thierry Christiaens
Journal:  Can Fam Physician       Date:  2010-11       Impact factor: 3.275

3.  Z-drugs.

Authors:  Stephen McCabe
Journal:  Br J Gen Pract       Date:  2007-03       Impact factor: 5.386

Review 4.  Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia.

Authors:  Stephanie L Harrison; Monica Cations; Tiffany Jessop; Sarah N Hilmer; Mouna Sawan; Henry Brodaty
Journal:  Drugs Aging       Date:  2019-02       Impact factor: 3.923

5.  Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population.

Authors:  Meldon Kahan; Angela Mailis-Gagnon; Lynn Wilson; Anita Srivastava
Journal:  Can Fam Physician       Date:  2011-11       Impact factor: 3.275

6.  Applying the intervention Complexity Assessment Tool to brief interventions targeting long-term benzodiazepine receptor agonist use in primary care: Lessons learned.

Authors:  Aisling Barry; Simon Lewin; Cathal A Cadogan
Journal:  BMC Prim Care       Date:  2022-07-16

7.  Efficacy of two interventions on the discontinuation of benzodiazepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care.

Authors:  Caterina Vicens; Ermengol Sempere; Ferrán Bejarano; Isabel Socias; Catalina Mateu; Francisca Fiol; Vicente Palop; Marta Mengual; Silvia Folch; Guillem Lera; Josep Basora; Alfonso Leiva
Journal:  Br J Gen Pract       Date:  2016-02       Impact factor: 5.386

8.  Comparative efficacy of two primary care interventions to assist withdrawal from long term benzodiazepine use: a protocol for a clustered, randomized clinical trial.

Authors:  Caterina Vicens; Isabel Socias; Catalina Mateu; Alfonso Leiva; Ferran Bejarano; Ermengol Sempere; Josep Basora; Vicente Palop; Marta Mengual; Jose Luis Beltran; Enric Aragonès; Guillem Lera; Silvia Folch; Josep Lluís Piñol; Magdalena Esteva; Miguel Roca; Arturo Arenas; María Del Mar Sureda; Francisco Campoamor; Francisca Fiol
Journal:  BMC Fam Pract       Date:  2011-04-20       Impact factor: 2.497

Review 9.  Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review.

Authors:  André S Pollmann; Andrea L Murphy; Joel C Bergman; David M Gardner
Journal:  BMC Pharmacol Toxicol       Date:  2015-07-04       Impact factor: 2.483

10.  An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial.

Authors:  Philippe Martin; Robyn Tamblyn; Sara Ahmed; Cara Tannenbaum
Journal:  Trials       Date:  2013-03-20       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.